21 - 23 May | Boston, USA

ALS Drug Development

This event focuses on providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.  

Conference website

ALS Drug Development

This event focuses on providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.  

Conference website

We are sponsors at this event!

Come and visit our team at our booth and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.

More details coming soon!

Arrange a meeting

Related pages

News Read our latest updates and press coverage
Blog Learn more about cells, our products, company and culture
About us Find out more about us and our people